Ocugen (OCGN)
Develops modifier gene therapies for inherited and degenerative blindness diseases.
$1.01
vs last close−0.03 (−2.88%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
−$0.06
Revenue estimate
$1.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.05−$0.05−$0.05−$0.07−$0.06−$0.06−$0.07Pending
Estimate−$0.05−$0.06−$0.06−$0.06−$0.06−$0.05−$0.05−$0.06
Surprise0.0%+16.7%+16.7%−21.7%0.0%−20.0%−31.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$764.0K$1.5M$1.4M$1.8M−$193.0K$1.5M$1.5MPending
Estimate$400.0K—$300.0K$440.0K$1.1M$417.8K$888.8K$1.1M
Surprise+91.0%—+357.7%+298.2%−118.0%+266.9%+67.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.00 | — | — |
| Sep 2028 | $0.00 | — | — |
| Jun 2028 | $0.00 | — | — |
| Mar 2028 | $0.00 | — | — |
| Dec 2027 | −$0.05 | — | — |
| Sep 2027 | −$0.09 | — | — |
| Jun 2027 | −$0.09 | — | — |
| Mar 2027 | −$0.07 | — | — |
| Dec 2026 | −$0.07 | — | — |
| Nov 2026 | −$0.06 | — | — |
| Aug 2026 | −$0.05 | −$0.07 | −31.3% |
| May 2026 | −$0.05 | −$0.06 | −20.0% |
| Mar 2026 | −$0.06 | −$0.06 | 0.0% |
| Nov 2025 | −$0.06 | −$0.07 | −21.7% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Apr 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.00 | — | — | $109.8M | — | — | — |
| Sep 2028 | $0.00 | — | — | $105.7M | — | — | — |
| Jun 2028 | $0.00 | — | — | $97.6M | — | — | — |
| Mar 2028 | $0.00 | — | — | $93.5M | — | — | — |
| Dec 2027 | −$0.05 | — | — | $17.7M | — | — | — |
| Sep 2027 | −$0.09 | — | — | $47.9M | — | — | — |
| Jun 2027 | −$0.09 | — | — | $1.8M | — | — | — |
| Mar 2027 | −$0.07 | — | — | $1.8M | — | — | — |
| Dec 2026 | −$0.07 | — | — | $1.0M | — | — | — |
| Nov 4, 2026 | −$0.06 | — | — | $1.1M | — | — | — |
| Aug 6, 2026 | −$0.05 | −$0.07 | −31.3% | $888.8K | $1.5M | +67.4% | −3.1% |
| May 5, 2026 | −$0.05 | −$0.06 | −20.0% | $417.8K | $1.5M | +266.9% | −19.5% |
| Mar 4, 2026 | −$0.06 | −$0.06 | 0.0% | $1.1M | −$193.0K | −118.0% | +5.4% |
| Nov 5, 2025 | −$0.06 | −$0.07 | −21.7% | $440.0K | $1.8M | +298.2% | −1.4% |
| Aug 1, 2025 | |||||||
| May 9, 2025 | |||||||
| Mar 5, 2025 | |||||||
| Nov 8, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 14, 2024 | |||||||
| Apr 2, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 21, 2023 | |||||||
| May 5, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 5, 2022 | |||||||
| May 6, 2022 | |||||||
| Feb 25, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 6, 2021 | |||||||
| May 7, 2021 | |||||||
| Mar 18, 2021 | |||||||
| Nov 6, 2020 | |||||||
| Aug 14, 2020 | |||||||
| May 8, 2020 | |||||||
| Mar 27, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 9, 2019 | |||||||
| May 15, 2019 | |||||||
| Mar 22, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 15, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 10, 2017 | |||||||
| May 11, 2017 | |||||||
| Mar 16, 2017 | |||||||
| Nov 10, 2016 | |||||||
| Aug 11, 2016 | |||||||
| May 12, 2016 | |||||||
| Mar 10, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 12, 2015 |